Patel S B, Honda A, Salen G
Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas 75235-9052, USA.
J Lipid Res. 1998 May;39(5):1055-61.
Sitosterolemia (phytosterolemia) is a rare autosomal recessively inherited disorder that is characterized by premature coronary artery disease, xanthomas, and increased plasma plant sterols and 5alpha-stanols. Affected individuals show an increased absorption of both cholesterol and sitosterol from the diet, decreased bile clearance of these sterols and their metabolites resulting in markedly expanded whole body cholesterol and sitosterol pools. Biochemical studies have shown that the regulation of the cholesterol biosynthetic pathway may be abnormal in this condition. In particular, the activities and mRNA for the biosynthetic enzymes, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and HMG-CoA synthase are low in liver biopsy specimens isolated from affected individuals, suggesting replete intracellular cholesterol pools. However, the membrane expression of hepatocyte low density lipoprotein receptors was increased, suggesting discordant regulation. Segregation analyses in three families for the genes for HMG-CoA reductase, HMG-CoA synthase, and LDL-receptor excluded these as sites of mutation. In view of the previously described discordant regulation of the above genes in sitosterolemia, the two major regulatory genes for this pathway, sterol regulatory element binding proteins (SREBP-1 and -2), were also examined. These genes did not segregate with the disease and were thus excluded. Two other genes involved in cholesterol absorption and chylomicron secretion, namely acyl coenzyme A:cholesterol acyltransferase (ACAT) and microsomal triglyceride transfer protein (MTP) were also examined for segregation and similarly excluded. Although the gene defect in sitosterolemia therefore remains to be elucidated, important candidate genes have been excluded.
谷甾醇血症(植物甾醇血症)是一种罕见的常染色体隐性遗传疾病,其特征为早发性冠状动脉疾病、黄色瘤以及血浆植物甾醇和5α-甾烷醇水平升高。患病个体从饮食中吸收胆固醇和谷甾醇的量增加,这些甾醇及其代谢产物的胆汁清除率降低,导致全身胆固醇和谷甾醇池显著扩大。生化研究表明,在这种情况下胆固醇生物合成途径的调节可能异常。特别是,从患病个体分离的肝活检标本中,生物合成酶3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶和HMG-CoA合酶的活性及mRNA水平较低,提示细胞内胆固醇池充足。然而,肝细胞低密度脂蛋白受体的膜表达增加,提示调节不一致。对三个家系中HMG-CoA还原酶、HMG-CoA合酶和低密度脂蛋白受体基因的分离分析排除了这些基因作为突变位点。鉴于先前描述的谷甾醇血症中上述基因调节不一致的情况,还对该途径的两个主要调节基因,即甾醇调节元件结合蛋白(SREBP-1和-2)进行了检查。这些基因与疾病不连锁,因此被排除。还检查了另外两个参与胆固醇吸收和乳糜微粒分泌的基因,即酰基辅酶A:胆固醇酰基转移酶(ACAT)和微粒体甘油三酯转移蛋白(MTP)的分离情况,同样排除了它们。因此,尽管谷甾醇血症的基因缺陷仍有待阐明,但重要的候选基因已被排除。